Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Collegium Pharmaceutical, Inc. (NASDAQ: COLL).

Full DD Report for COLL

You must become a subscriber to view this report.


Recent News from (NASDAQ: COLL)

Senate vote approaches on bill to combat opioid crisis
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 07 2018 12:48
Collegium Announces Scientific Presentations at PAINWeek 2018 Meeting
STOUGHTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has supported the following poster presentations on tapentadol (Nucynta® and Nucynta® ER), at PAINWeek 2018 on September 6th in Las Vegas. The following pos...
Source: GlobeNewswire
Date: September, 04 2018 10:01
FDA updates on multifaceted plan to combat opioid crisis
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 29 2018 12:44
FDA clamps down on opioid-peddling websites
The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc...
Source: SeekingAlpha
Date: August, 28 2018 10:57
Report: Exploring Fundamental Drivers Behind Fiesta Restaurant Group, Emerge Energy Services LP, Collegium Pharmaceutical, Cutera, Resources Connection, and Spark Therapeutics - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Aug. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fiesta Restaurant Group, Inc. (NASDAQ:FRGI), Emerge Energy Services LP (N...
Source: GlobeNewswire
Date: August, 24 2018 07:30
FDA awards contract to develop guidelines for opioid prescribing
The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND...
Source: SeekingAlpha
Date: August, 22 2018 11:16
White House proposing cuts in opioid production
Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &...
Source: SeekingAlpha
Date: August, 16 2018 15:24
Investors shun healthcare stocks in broad market selloff
Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc...
Source: SeekingAlpha
Date: August, 15 2018 10:14
Collegium: Soft Reaction To Softer Growth
Collegium Pharmaceutical ( COLL ) continues to hold a dominant position in my portfolio as the potential of Xtampza appeals to me, potentially playing a key role in tackling the opioid crisis. The gradual rise of Xtampza sales and modest valuation is what attracted me to the stock, althoug...
Source: SeekingAlpha
Date: August, 10 2018 05:15
Collegium Pharmaceutical's (COLL) CEO Joe Ciaffoni on Q2 2018 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET Executives Shirley Kuhlmann – General Counsel Joe Ciaffoni – Chief Executive Officer Scott Dreyer – Chief Commercial Officer Paul Brannelly – Chief Finan...
Source: SeekingAlpha
Date: August, 08 2018 22:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0815.2715.8116.26515.20477,083
2018-05-1724.5725.2025.3324.19287,938
2017-02-0316.1215.7016.17515.43292,908
2017-02-0216.9516.1017.0315.98400,797
2017-02-0117.0016.9917.6016.71307,569

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1853,82475,26471.5136Short
2018-12-17141,674171,37182.6709Short
2018-12-1472,222130,00055.5554Short
2018-12-1339,53585,20346.4009Short
2018-12-1231,10083,74037.1388Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on COLL.


About Collegium Pharmaceutical, Inc. (NASDAQ: COLL)

Logo for Collegium Pharmaceutical, Inc. (NASDAQ: COLL)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $833,425,762 - 05/15/2018
  • Issue and Outstanding: 32,993,894 - 03/01/2018

 


Recent Filings from (NASDAQ: COLL)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 13 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: COLL)

Daily Technical Chart for (NASDAQ: COLL)


Stay tuned for daily updates and more on (NASDAQ: COLL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: COLL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in COLL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of COLL and does not buy, sell, or trade any shares of COLL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/